Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Jakafi
Pharma
J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD
Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease.
Kevin Dunleavy
Aug 25, 2022 9:37am
Incyte's Opzelura slapped with vitiligo decision delay
Mar 14, 2022 11:28am
Incyte's eczema cream Opzelura combats payer hurdles: exec
Nov 2, 2021 10:55am
Jakafi maker Incyte channels blood test anxiety in awareness ads
Oct 12, 2021 11:05am
Incyte snags 2nd JAK nod in 2 days—this time for Jakafi
Sep 23, 2021 10:20am
Incyte still counts on Jakafi, rux cream September PDUFAs
Aug 4, 2021 11:12am